INTRODUCTION
Peripheral serotonin (5-hydroxytryptamine, 5-HT) influences the physiopathology of numerous tissues [1] [2] [3] as it controls vascular, heart and gastrointestinal functions 4, 5 , promotes cell proliferation [6] [7] [8] [9] , regulates wound healing, and influences immune and inflammatory responses 10 by modulating T lymphocyte 11 and myeloid cell functions [12] [13] [14] [15] [16] . In inflammatory pathologies, 5-HT contributes to Pulmonary Arterial Hypertension (PAH) 17 , atopic dermatitis 18 , systemic sclerosis 19 , inflammatory gut disorders [20] [21] [22] [23] [24] [25] , cancer angiogenesis 26 and neuroendocrine neoplasms proliferation 27 , whereas it reduces pathologic scores in collageninduced arthritis 28 . The existence of seven types of 5-HT receptors (5-HT 1-7 ), with different distribution and signaling properties 29 , underlies these tissue-specific actions of 5-HT.
Macrophages promote the initiation and the resolution of inflammatory processes, with both processes being essential for maintaining tissue homeostasis [30] [31] [32] . In fact, modulation of macrophage polarization is an attractive therapeutic target for chronic inflammatory pathologies, where the balance between pro-inflammatory and resolving macrophages is altered 33, 34 . Not surprisingly, macrophage effector functions are directly modulated by 5-HT 17, 22, 26, 35, 36 , and also by Selective Serotonin Reuptake Inhibitors (SSRI) 37, 38 . We have previously demonstrated that 5-HT 7 is the major mediator of the anti-inflammatory actions of 5-HT on human macrophages 39 and that both 5-HT 2B and 5-HT 7 contribute to the maintenance of the anti-inflammatory state of M-CSF-dependent human macrophages 40 .
The 5-HT 2B serotonin receptor is expressed in the central nervous system, where it exerts antidepressant or anxiolytic-like effects 41 , and in periphery, where it plays a major role in heart development 42 . Pharmacologic and genetic studies indicate that 5-HT 2B is required for 5-HTmediated pathologies like PAH 17, 43 , dermal, lung and liver fibrosis 19, 44, 45 , cardiac hypertrophy 46, 47 , and mediates the valvular heart disease (VHD) and fibrosis associated with carcinoid syndrome 48 . Importantly, anti-migraine drugs like methysergide and ergotamine 49, 50 , general anesthetics 51 , fenfluramine and conventional SSRIs [52] [53] [54] [55] , and even the dopamine agonists and anti-parkinsonian drugs pergolide and cabergoline 50, 56, 57 , exert potent off-target effects on 5-HT 2B
50
. In fact, 5-HT 2B appears to be required for the therapeutic actions of SSRI 54 . Since some of these 5-HT 2B -targeting drugs induce VHD, their use is restricted, and novel potential drugs are commonly screened for 5-HT 2B agonist activity.
5-HT 2B engagement enhances proliferation of numerous cell types 9,58-67 via Gαq and Src phosphorylation, and through production of growth factors like insulin 68 , TGFβ1, CTGF, FGF2 45, 60 and TGFα 69 . In macrophages, 5-HT 2B prevents mononuclear phagocyte degeneration in amyotrophic lateral sclerosis 70 , and Htr2b -/-microglia exhibits a mild inflammatory state 71 , which is in line with the ability of 5-HT 2B antagonist SB204741 to impair the acquisition of human macrophage polarization-specific genes 40 and TGFβ1 expression by mouse Kupffer cells 45 . However, although 5-HT 2B activation modifies inflammatory cytokine production by human monocytes 72 , the functional and transcriptional consequences of 5-HT 2B ligation in human macrophage remains to be determined. Since antiinflammatory M-CSF-dependent macrophages express 5-HT 2B , we have assessed the specific role of 5-HT 2B in macrophage polarization. The use of the 5-HT 2B agonist BW723C86, used to evaluate the role of 5-HT 2B in preclinical models of depression 54 and anxiety 73, 74 , allowed us to demonstrate that 5-HT 2B shapes the macrophage transcriptome via Aryl hydrocarbon Receptor (AhR) activation and impairs the osteoclastogenic potential of human macrophages. 85 , amply used as in vivo 54, 73, 74, [86] [87] [88] [89] [90] [91] and ex vivo 28, 66, 70 , and with potential therapeutic effects 73, 74, 91 . Altogether, these results demonstrate that BW723C86 modifies the macrophage transcriptome through 5-HT 2B -dependent (SB204741-sensitive) and 5-HT 2B -independent mechanisms.
METHODS

Generation
BW723C86 modifies the LPS-induced cytokine and gene profile. As GSEA revealed that BW723C86 downregulates the "TNFα Signaling via NFκβ" and "Inflammatory Response" gene sets ( Figure 1D ), we next assessed the ability of BW723C86 to alter macrophage responses to an inflammatory stimulus like LPS (Figure 2A ). BW723C86 did not modify basal cytokine production by M-MØ ( Figure 2B and not shown), while it significantly reduced TNFα production, and increased CCL2 release, from LPS-treated M-MØ ( Figure   2B ). A similar trend was observed with α-Methyl Serotonin (AMS), a less selective 5-HT 2B agonist 77 , although its effects did not reach statistical significance (data not shown).
Importantly, the effect of BW723C86 on cytokine production by LPS-activated M-MØ was Table VI) .
Based on these findings, we assessed the ability of BW723C86 to upregulate the expression of xenobiotic response genes, and found that exposure to BW723C86 significantly upregulates AhR target genes (AHRR, CYP1B1, SERPINB2, TIPARP, EREG) 98,100 ( Figure 3C ). Their upregulation was detected as early as 2 hours after addition of BW723C86 ( Figure 3D ), observed at BW723C86 concentrations between 0.1 μM and 10 μM ( Figure 3E ) and confirmed on 5-HT 2B -expressing human hepatoma HepG2 cells ( Figure 3F ). In agreement with microarray data, upregulation of AhR-target genes by BW723C86 was reduced by the 5-HT 2B antagonist SB204741 ( Figure 3G ). Therefore, the BW723C86 agonist upregulates the expression of AhR target genes in human macrophages in a 5-HT 2B -dependent manner. Figure   5C ). However, the BW723C86-mediated upregulation of CYP1B1 was prevented in the presence of 100 μM 5-HT that, by contrast, did not affect the ability of BW723C86 to downregulate OCTSAMP expression ( Figure 5C ). Therefore, 5-HT impairs the ability of the 5-HT 2B agonist BW723C86 to activate the AhR transcriptional activity in human macrophages. significantly augmented the expression of IRF8, whose protein product negatively regulates osteoclast differentiation 107 , and simultaneously provoked a significant reduction in the expression of PRDM1, whose encoded protein (Blimp1) represses the expression of negative regulators of osteoclast differentiation 107, 109, 110 ( Figure 7B ). In fact, exposure of M-MØ to BW723C86 for 6 hours sufficed to significantly downregulate the expression of PRDM1 (Supplementary Table II ). In consonance with these results, the continuous presence of BW723C86 greatly impaired the generation of "ruffled border"-rich multinucleated cells during the M-CSF+RANKL-driven osteoclast differentiation, as seen by light microscopy ( Figure 7C ) and after TRAP staining ( Figure 7D ). Therefore, BW723C86 has an inhibitory effect on the ability of human monocytes to differentiate into osteoclasts at the transcriptional and morphological level, an effect that correlates with its ability to down-regulate PRDM1 expression and to enhance the expression of IRF8.
5-HT
DISCUSSION
The polarization-specific expression of 5-HT 2B , an unintended target of commonly used drugs, prompted us to dissect the transcriptional consequences of 5-HT 2B activation in human macrophages through the use of the 5-HT 2B agonist BW723C86, which exhibits good selectivity for 5-HT 2B 85 , and the 5-HT 2B antagonist SB204741, with exerts selectivity over 5- Innovación.
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